Cargando…
Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
PURPOSE: To describe the visual acuity and safety outcomes for the first 50 patients with neovascular age-related macular degeneration (nAMD) treated with ranibizumab at Moorfields Eye Hospital. METHODS: A retrospective analysis of case notes from the first 50 consecutive patients with Primary Care...
Autores principales: | Rotsos, Tryfon, Patel, Praveen J, Chen, Fred K, Tufail, Adnan |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2993128/ https://www.ncbi.nlm.nih.gov/pubmed/21151333 http://dx.doi.org/10.2147/OPTH.S14684 |
Ejemplares similares
-
Management of Neovascular Age-Related Macular Degeneration in Clinical Practice: Initiation, Maintenance, and Discontinuation of Therapy
por: Keane, Pearse A., et al.
Publicado: (2011) -
Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006) -
Missed Hospital Appointments of Patients Receiving Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration
por: Karampelas, Michael, et al.
Publicado: (2015) -
Ranibizumab therapy for predominantly hemorrhagic neovascular age-related macular degeneration
por: Dikmetas, Ozlem, et al.
Publicado: (2022) -
Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
por: Hurley, Susan F, et al.
Publicado: (2008)